Key result
SGLT2 inhibitors are linked to reduced cancer therapy-related cardiac dysfunction, especially with anthracycline exposure.
Why the study?
Recent data suggest sodium-glucose cotransporter 2 inhibitors have cardioprotective benefits that may extend to cancer therapy-related cardiac dysfunction beyond glycemic control.
Do sodium-glucose cotransporter 2 inhibitors prevent cancer therapy-related cardiac dysfunction in patients undergoing cancer treatment?
Do sodium-glucose cotransporter 2 inhibitors prevent cancer therapy-related cardiac dysfunction in patients undergoing cancer treatment?
Answers are grounded in this paper and cite their sources.
This review highlights the emerging role of SGLT2 inhibitors as a potential primary prevention and treatment strategy for cancer therapy-related cardiac dysfunction, extending their established cardioprotective benefits to cardio-oncology.
Recent data suggest that sodium-glucose cotransporter 2 inhibitors have cardioprotective benefits. This effect may extend towards cardioprotection in cancer therapy-related cardiac dysfunction, with proposed mechanisms extending beyond glycemic control to include anti-inflammatory effects, oxidative stress reduction, and metabolic reprogramming. This review synthesizes potential mechanisms, observational data, and emerging trial evidence to support sodium-glucose cotransporter 2 inhibitors as a primary prevention strategy for cancer therapy-related cardiac dysfunction, particularly in anthracycline-exposed populations.
No takes yet. Share an insight, caveat, or question.
Steinberg et al. (2026) conducted a review in Cancer therapy-related cardiac dysfunction. Sodium-glucose cotransporter 2 inhibitors was evaluated. SGLT2 inhibitors show promise as a primary prevention strategy for cancer therapy-related cardiac dysfunction, particularly in anthracycline-exposed populations, based on observational data.
Synapse has enriched 10 related papers. Consider them for comparative context: